A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
Phase 3
Completed
- Conditions
- HyperlipidemiaDyslipidemiaHypercholesterolemia
- Registration Number
- NCT00267254
- Lead Sponsor
- Pfizer
- Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.
- Detailed Description
For additional information please call: 1-800-718-1021
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 640
Inclusion Criteria
- eligible for statin treatment for LDL cholesterol by NCEP guidelines
Exclusion Criteria
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
- Subjects with significant liver or kidney disease or significant heart failure.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
- Secondary Outcome Measures
Name Time Method Changes in other lipid parameters and other biomarkers.
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Milwaukee, Wisconsin, United States